Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Corbus Pharmaceuticals (CRBP) will host a virtual conference call and webcast on Monday, September 14, 2026, at 8:00 a.m. EDT to discuss topline data from CANYON-1, a Phase 1b study of obesity candidate CRB-913.

Rhea-AI Summary

Corbus Pharmaceuticals (CRBP) will host a virtual conference call and webcast on Monday, September 14, 2026, at 8:00 a.m. EDT to discuss topline data from CANYON-1, a Phase 1b study of obesity candidate CRB-913.

The 16-week double-blind, placebo-controlled, dose-ranging trial enrolls 240 obese, non-diabetic adults across multiple U.S. sites, with once-daily oral doses of 20 mg, 40 mg, or 60 mg CRB-913 versus placebo. All CRB-913 participants start at 20 mg/day and titrate to their assigned dose, receive 12 weeks of treatment, and then have a four-week safety follow-up. Investigator Harold Bays, M.D., will join as a guest speaker, and a replay will be available on the Corbus website.

Argus 15 min delay

+18.60% vs previous close $9.63 last price 1.4x rel. volume Open Argus

Details

Market Reaction – CRBP

-6.9% Trough in 11 min

$7.95 $9.72 Day Range

$186.26M Market Cap

Following this news, CRBP has gained 18.60%, reflecting a significant positive market reaction. Argus tracked a trough of -6.9% from its starting point during tracking. Our momentum scanner has triggered 5 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $9.63.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Study phase: Phase 1b Sample size: 240 participants Study duration: 16 weeks +3 more

Study phase

Phase 1b

CANYON-1 obesity study

Sample size

240 participants

Obese, non-diabetic adults

Study duration

16 weeks

Double-blind, placebo-controlled study

Dose cohorts

20 mg, 40 mg, and 60 mg

Once-daily CRB-913 cohorts plus placebo

Treatment period

12 weeks

Participants were dosed before safety follow-up

Safety follow-up

4 weeks

After dosing

Key Terms

cb1 inverse agonist, glp-1, double-blind, placebo-controlled, +1 more

5 terms

cb1 inverse agonist medical

"a highly peripherally restricted oral CB1 inverse agonist"

A CB1 inverse agonist is a drug that binds to the brain and nervous system’s CB1 cannabinoid receptor and pushes its activity below its normal resting level, producing effects opposite to those of cannabis-like stimulation. For investors, these drugs matter because altering appetite, mood, pain or addiction pathways can create significant market opportunities or regulatory risks—think of it as turning a dimmer switch lower than the factory setting to achieve a different therapeutic outcome.

glp-1 medical

"beyond GLP-1 and other incretin-targeting therapies"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

double-blind medical

"a 16-week double-blind, placebo-controlled, dose-ranging study"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"a 16-week double-blind, placebo-controlled, dose-ranging study"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

dose-ranging medical

"a 16-week double-blind, placebo-controlled, dose-ranging study"

A dose-ranging study is a clinical trial that tests multiple amounts of a drug to find what dose works best and is safest, much like trying different spice levels in a recipe to get the right balance. For investors, results clarify whether a medicine is effective at practical doses, how likely it is to win regulatory approval, what side effects to expect, and how the treatment might be priced and used in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Virtual Webcast to be Held Monday, September 14, 2026, at 8:00 AM EDT

NORWOOD, Mass., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on developing new therapies in oncology and obesity, today announced that the Company’s management team will host a conference call webcast on Monday, September 14 at 8:00 a.m. EDT, to discuss topline data for CANYON-1, a Phase 1b study of CRB-913 for the treatment of obesity. Harold Bays, M.D., an investigator for the study, will be a guest speaker in the event. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management and a new therapeutic option for obesity beyond GLP-1 and other incretin-targeting therapies.

The CANYON-1 Phase 1b clinical trial is a 16-week double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic adult participants conducted at multiple clinical sites in the United States (NCT07310901). The trial includes three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily (QD) as well as a placebo cohort (randomization of 1:1:1:1). A dose titration regimen was included in the design, with all participants receiving CRB-913 commencing at 20 mg/day and then titrating up to either 40 mg/day or beyond that to 60 mg/day, depending on their assigned cohorts. Participants were dosed for 12 weeks followed by a four-week safety follow-up.

Registration Details
Date:	Monday, September 14, 2026
Time:	8:00 a.m. EDT
Registration:	Click here
A replay will be available on the Corbus website following the event.

About Harold Bays, M.D.

Dr. Harold Bays is Board Certified in Endocrinology and Internal Medicine, Diplomate of the American Board of Obesity Medicine and Diplomate of the American Board of Clinical Lipidology. He is Medical Director Louisville Metabolic and Atherosclerosis Research Center/ Monroe Biomedical Research and Clinical Associate Professor at the University of Louisville School of Medicine. He has served as an Investigator for over 700 Phase I - IV clinical trials regarding treatments for obesity, dyslipidemias, diabetes mellitus, hypertension, and other cardiometabolic and hormonal disorders. Dr. Bays is Chief Science Officer of the Obesity Medicine Association and is Editor in Chief for Obesity Pillars – the journal of the Obesity Medicine Association. Dr. Bays was President of the Obesity Medicine Association in 2025 – 2026. Dr. Bays has written and/or served as a contributing author for approximately 400 peer review scientific manuscripts and book chapters, hundreds of scientific abstracts presented at major scientific meetings. He has served as first author and/or co-author for scientific consensus statements, position statements, and clinical practice statements in Obesity Medicine and Clinical Lipidology. He is a Fellow of the Obesity Medicine Association (FOMA), Fellow of the National Lipid Association (FNLA), Fellow of The Obesity Society (FTOS), Fellow of the American College of Cardiology (FACC), and Fellow of the American Society of Preventive Cardiology (FASPC). Dr. Bays originated the term "adiposopathy" ("sick fat"), which defines how and when the pathogenic consequences of adipose tissue accumulation promote metabolic disease, including dyslipidemia, diabetes mellitus, and hypertension. Dr. Bays has received several scientific awards in such as the 2016 Obesity Medicine Association “Obesity Medicine Association Clinician of the Year,” 2026 Obesity Medicine Association Research Award, and 2015 National Lipid Association “President’s Service Award.” Finally, in 2026, Clarivate designated Dr. Bays as a “Highly Cited Researcher,” defined as having authored “multiple Highly Cited Papers that rank in the top 1% by citations for their field(s) and publication year in the Web of Science Core Collection - indicating exceptional influence in their respective disciplines.”

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act of 1995, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, anticipated timing for initiation of clinical trials, anticipated regulatory interactions and outcomes, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities, sufficiency of cash runway and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission including those described in our Annual Report on Form 10-K for the year ended December 31, 2025. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.

INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
smoran@corbuspharma.com

Dan Ferry
Managing Director
LifeSci Advisors, LLC
daniel@lifesciadvisors.com

MEDIA CONTACT:
Liz Melone
Founder & Principal
Melone Communications, LLC
liz@melonecomm.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Corbus host the webcast on CANYON-1 topline data?

The webcast and conference call will take place on Monday, September 14, 2026, at 8:00 a.m. EDT.

What is the design of the CANYON-1 Phase 1b trial of CRB-913?

CANYON-1 is a 16-week, double-blind, placebo-controlled, dose-ranging Phase 1b trial in 240 obese, non-diabetic adult participants at multiple U.S. sites, with oral once-daily CRB-913 doses of 20 mg, 40 mg, or 60 mg versus placebo in a 1:1:1:1 randomization.

How is CRB-913 dosed and titrated in the CANYON-1 study?

All participants receiving CRB-913 start at 20 mg/day and then titrate up to 40 mg/day or 60 mg/day, depending on their assigned cohort, with 12 weeks of dosing followed by a four-week safety follow-up.

What type of drug is CRB-913 and what obesity treatment approach does it represent?

CRB-913 is described as a once-daily, highly peripherally restricted oral CB1 inverse agonist, which the company views as an orthogonal approach to weight loss and long-term weight management and a potential option beyond GLP-1 and other incretin-targeting therapies.

Will there be access to the CANYON-1 webcast after the live event?

Yes. A replay of the webcast will be available on the Corbus website following the event.